Gene
CRBN
CRBN is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (6), Trial mentions (4), Target-disease associations (298), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CRBN. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 7 at the structurally incomplete recent edge.
CRBN has 4 trial mentions across 4 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 12 of 11,460 | 0.10% |
| 2022 | 1 of 8,285 | 0.01% | 7 of 13,598 | 0.05% |
| 2021 | 0 of 8,692 | 0.00% | 14 of 15,045 | 0.09% |
| 2020 | 1 of 7,640 | 0.01% | 8 of 14,459 | 0.06% |
| 2019 | 0 of 7,300 | 0.00% | 9 of 12,159 | 0.07% |
| 2018 | 0 of 6,927 | 0.00% | 2 of 11,854 | 0.02% |
| 2017 | 0 of 6,558 | 0.00% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
Actionable biomarkers (6)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CRBN oncogenic mutation | LENALIDOMIDE | responsive | multiple myeloma | Cancer Genome Interpreter |
| CRBN (Q100*,R283K) | LENALIDOMIDE | responsive | multiple myeloma | Cancer Genome Interpreter |
| CRBN undexpression | LENALIDOMIDE | responsive | multiple myeloma | Cancer Genome Interpreter |
| CRBN undexpression | POMALIDOMIDE | responsive | multiple myeloma | Cancer Genome Interpreter |
| CRBN oncogenic mutation | POMALIDOMIDE | responsive | multiple myeloma | Cancer Genome Interpreter |
Showing 5 of 6 actionable-biomarker assertions.
Trial mentions (4)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04434196 | Trial eligibility (AACT) |
| NCT05169515 | Trial eligibility (AACT) |
| NCT05583617 | Trial eligibility (AACT) |
| NCT01675141 | Trial outcomes (AACT) |
Target-disease associations (298)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4) measurement | measurement | GWAS credible sets |
| 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) measurement | measurement | GWAS credible sets |
| 3-methylglutaconic aciduria type 1 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| AIDS | genetic, familial or congenital disease | Clinical precedence |
| AKT2-related familial partial lipodystrophy | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 298 associations.
Vendor sourcing (17)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is observed at an extremely low frequency in the gnomAD v4.1.0 dataset (total allele frequency: <0.001%). Predicted Consequence/Location: Intron ... | View ClinVar record SCV007609110.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV002663653.2 |
| Celgene (United States) | Trial collaborator | Mentioned in trial textTrial free-text mention | CRBN | View trial NCT01675141 |
| Celgene (United States) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Presence of any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the ... | View trial NCT04434196 |
| Celgene (United States) | Trial sponsor | Mentioned in trial textTrial free-text mention | CRBN | View trial NCT04434196 |
Showing 5 of 17 sourcing records.
Trial-cited literature (95)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. | The Lancet. Haematology | 2026 | 1 |
| Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. | Molecular cancer therapeutics | 2025 | 65 |
| A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomide. | Journal of pharmaceutical sciences | 2025 | 1 |
| ER degradation for ER<sup>+</sup>/HER2- advanced or metastatic breast cancer: a phase 1 trial. | Nature communications | 2025 | 0 |
| MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial. | Blood advances | 2024 | 15 |
Showing 5 of 95 papers.
Protein variant mentions (12)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A10G | 1 | 2015 | PMID 25741868 |
| p.C391R | 1 | 2013 | PMID 24088041 |
| p.D313H | 1 | 2015 | PMID 25741868 |
| p.D6H | 1 | 2015 | PMID 25741868 |
| p.E30K | 1 | 2015 | PMID 25741868 |
Showing 5 of 12 variants.
Literature-extracted relations (31)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Lipopolysaccharides | Chemical | associate |
CRBN knockdown mitigates lipopolysaccharide-induced acute lung injury by suppression of oxidative stress and endoplasmic reticulum (ER) stress associated NF-κB signaling. | 2020 |
| LENALIDOMIDE | Chemical | associate |
Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. | 2020 |
| LENALIDOMIDE | Chemical | associate |
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. | 2019 |
| THALIDOMIDE | Chemical | associate |
[Cereblon as a primary target of IMiDs]. | 2019 |
| LENALIDOMIDE | Chemical | interact |
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. | 2018 |
Showing 5 of 31 relation assertions.
Organizations publishing (158)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mayo Clinic | Hospital | 12 | 2011 to 2023 |
| Government of the United States of America | Government | 8 | 2012 to 2023 |
| Dana-Farber Cancer Institute | Other | 7 | 2014 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 5 | 2019 to 2023 |
| Harvard Medical School | Academic | 4 | 2014 to 2022 |
Showing 5 of 158 organizations.
Where CRBN appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- respiratory or thoracic disease
276 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.